Efficacy of concurrent treatments in idiopathic pulmonary fibrosis patients with a rapid progression of respiratory failure: An analysis of a national administrative database in Japan

BMC Pulmonary Medicine

Volumn 16, Issue 1, 2016, Pages

  Oda, Keishi ^a   Yatera, Kazuhiro ^a   Fujino, Yoshihisa ^a   Ishimoto, Hiroshi ^a,d   Nakao, Hiroyuki ^b   Hanaka, Tetsuya ^a   Ogoshi, Takaaki ^a   Kido, Takashi ^a   Fushimi, Kiyohide ^c   Matsuda, Shinya ^a   Mukae, Hiroshi ^a,d  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Miyazaki Prefectural Nursing University   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute exacerbation of idiopathic pulmonary fibrosis; Acute respiratory failure; Co trimoxazole; Corticosteroid; Macrolide; Mechanical ventilation; Nationwide database

Indexed keywords

ANTICOAGULANT AGENT; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; MACROLIDE; METHYLPREDNISOLONE;

ADULT; AGE; AGED; ARTICLE; ARTIFICIAL VENTILATION; BRONCHOSCOPY; DRUG MEGADOSE; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; HOSPITAL ADMISSION; HUMAN; JAPANESE (PEOPLE); LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SEASONAL VARIATION; SHORT TERM SURVIVAL; SURVIVAL RATE; COMPLICATION; DISEASE COURSE; FACTUAL DATABASE; INTENSIVE CARE UNIT; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; RESPIRATORY INSUFFICIENCY; STATISTICAL MODEL; TREATMENT OUTCOME; VERY ELDERLY;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; BRONCHOSCOPY; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTENSIVE CARE UNITS; JAPAN; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MACROLIDES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 84975780405     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-016-0253-x     Document Type: Article

References (30)

1. Natsuizaka M, Chiba H, Kuronuma K, Otsuka M, Kudo K, Mori M, Bando M, Sugiyama Y, Takahashi H. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med. 2014;190(7):773-9.
2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
3. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest. 1993;103(6):1808-12.
4. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Lasky JA, Loyd JE, Noth I, Olman MA, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636-43.
5. Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir Med. 2008;102(10):1355-9.
6. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356-63.
7. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, investigators I. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14:73.
8. Oda K, Ishimoto H, Yamada S, Kushima H, Ishii H, Imanaga T, Harada T, Ishimatsu Y, Matsumoto N, Naito K, et al. Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis. Respir Res. 2014;15(1):109.
9. Juarez MM, Chan AL, Norris AG, Morrissey BM, Albertson TE. Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies. J Thorac Dis. 2015;7(3):499-519.
10. Kataoka K, Taniguchi H, Kondoh Y, Nishiyama O, Kimura T, Matsuda T, Yokoyama T, Sakamoto K, Ando M. Recombinant human thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis. Chest 2015;148(2):436-43.
11. Bhatti H, Girdhar A, Usman F, Cury J, Bajwa A. Approach to acute exacerbation of idiopathic pulmonary fibrosis. Ann Thorac Med. 2013;8(2):71-7.
12. Antoniou KM, Wells AU. Acute exacerbations of idiopathic pulmonary fibrosis. Respiration. 2013;86(4):265-74.
13. Kuwabara K, Matsuda S, Fushimi K, Ishikawa KB, Horiguchi H, Hayashida K, Fujimori K. Contribution of case-mix classification to profiling hospital characteristics and productivity. Int J Health Plann Manage. 2011;26(3):e138-50.
14. FLETCHER CM. The clinical diagnosis of pulmonary emphysema; an experimental study. Proc R Soc Med. 1952;45(9):577-84.
15. Gaudry S, Vincent F, Rabbat A, Nunes H, Crestani B, Naccache JM, Wolff M, Thabut G, Valeyre D, Cohen Y, et al. Invasive mechanical ventilation in patients with fibrosing interstitial pneumonia. J Thorac Cardiovasc Surg. 2014;147(1):47-53.
16. Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, Collard HR. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566-72.
17. Olson AL, Swigris JJ, Raghu G, Brown KK. Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter. Chest. 2009;136(1):16-22.
18. Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM, Lederer DJ. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med. 2011;184(7):842-7.
19. Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM, Murphy E, Johnston SL, Schwartz DA, Wells AU, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190(8):906-13.
20. Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, Moore BB, White ES, Flaherty KR, Huffnagle GB, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014;2(7):548-56.
21. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27(1):143-50.
22. Collard HR, Loyd JE, King TE, Lancaster LH. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med. 2007;101(9):2011-6.
23. Shimizu Y, Sunaga N, Dobashi K, Fueki M, Fueki N, Makino S, Mori M. Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study. BMC Infect Dis. 2009;9:47.
24. Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Wilson EC, Twentyman OP, Davison AG, Curtin JJ, Crawford MB, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. 2013;68(2):155-62.
25. Huie TJ, Olson AL, Cosgrove GP, Janssen WJ, Lara AR, Lynch DA, Groshong SD, Moss M, Schwarz MI, Brown KK, et al. A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology. 2010;15(6):909-17.
26. Anderson R, Grabow G, Oosthuizen R, Theron A, Van Rensburg AJ. Effects of sulfamethoxazole and trimethoprim on human neutrophil and lymphocyte functions in vitro: in vivo effects of co-trimoxazole. Antimicrob Agents Chemother. 1980;17(3):322-6.
27. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23(3):590-615.
28. Ishimoto H, Mukae H, Sakamoto N, Amenomori M, Kitazaki T, Imamura Y, Fujita H, Ishii H, Nakayama S, Yanagihara K, et al. Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with azithromycin and clarithromycin. J Antimicrob Chemother. 2009;63(1):109-14.
29. Kawamura K, Ichikado K, Suga M, Yoshioka M. Efficacy of azithromycin for treatment of acute exacerbation of chronic fibrosing interstitial pneumonia: a prospective, open-label study with historical controls. Respiration. 2014;87(6):478-84.
30. Tzilas V, Bouros D. Inherent weaknesses of the current ICD coding system regarding idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(4):1194-6.